Cell/Gene Tx channel feed

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

5 days ago
R&D

Retro Bio­sciences inks blood dis­or­der deal as Sam Alt­man-backed biotech seeks $1B in funds

5 days ago
Startups
Deals

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

6 days ago
People
R&D

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

6 days ago
R&D
Pharma

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

6 days ago
R&D

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

Last week
R&D

In three pa­tients, Rock­et’s sec­ond heart gene ther­a­py shows promise

Last week
R&D

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Last week
Startups
Deals

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Last week
R&D
In Focus

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

Last week
R&D

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Last week
Law

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Last week
People

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Last week
Startups

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

3 weeks ago
R&D
In Focus

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

3 weeks ago
R&D

Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion

3 weeks ago
Financing
Startups

FDA ad­comm will re­view Capri­cor's cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy

3 weeks ago
Pharma
FDA+

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

3 weeks ago
R&D

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

3 weeks ago
R&D
China

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

4 weeks ago
R&D

Feng Zhang’s pro­tein nanopar­ti­cle start­up Aera Ther­a­peu­tics turns to lipid nanopar­ti­cles to jump­start its pipeline

4 weeks ago
R&D

Bris­tol My­ers to close cell ther­a­py site in Illi­nois as part of on­go­ing cost cuts

4 weeks ago
People
Manufacturing

FDA ap­proves Abeona’s skin dis­ease cell ther­a­py

4 weeks ago
Pharma
FDA+

RFK Jr. touts CMS pro­gram test­ing new ways to pay for sick­le cell dis­ease treat­ment

5 weeks ago
Pharma
1234 Next page Last page
A service from the Financial Times